Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00066196 | Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma | PHASE2 | COMPLETED | 110 | — | — | Aug 1, 2003 | Jun 1, 2007 | Jan 15, 2008 | 25 | United States |
| Arm | Type | Description |
|---|---|---|
| 2 | OTHER | Integrin + Dacarbazine |
| 1 | ACTIVE_COMPARATOR | MEDI-522 |
| Name | Type | Description |
|---|---|---|
| MEDI--522 | BIOLOGICAL | IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL. |
| Integrin + Dacarbazine | BIOLOGICAL | supplied in other formulations |
Inclusion Patients must meet all of the following criteria at the time of randomization: * Histologically confirmed, unresectable, Stage IV metastatic melanoma (AJCC staging), with at least one measurable lesion defined as at least one lesion that can be accurately measured in at least one dimensi...